Listeners:
Top listeners:
Bone-on-Bone Arthritis: Why Injections Stop Working
Fatty Liver Is the New #1 Cause of Cirrhosis — Are You at Risk?
Ozempic Isn’t Dragon Venom — The Real Truth About GLP-1 Weight Loss
50% Pain Relief After a Joint Injection? That’s Actually a Win
Ozempic Won’t “Eat Your Muscle” — Here’s the Real Fix
The 3,500-Calorie Rule Works… Until It Doesn’t
Episode 2 days ago 0 Like
PLAY EPISODE
The lecture highlights the rising prevalence of fatty liver disease in obesity and diabetes, emphasizing early detection methods and limited treatments, while advocating for proactive health management and improved patient-provider communication.
In this episode, I’m focusing on fatty liver disease, a condition that is incredibly common and still easy to miss, especially in people living with obesity and type 2 diabetes. I use a real patient scenario from clinic to show how often this comes up in everyday primary care and why so many people are surprised to hear their liver may be at risk. I walk through the numbers and what they actually mean in real life, because fatty liver disease is not just a “benign finding” on a scan. Over time it can progress from simple fat buildup to inflammation, then fibrosis, and in some patients it advances to cirrhosis and even liver cancer. That progression is exactly why I keep coming back to early detection. Most people do not feel symptoms until late, which means waiting for symptoms is the wrong strategy. I explain the practical tools we use to catch this earlier, including a liver ultrasound and a simple scoring system called the FIB 4 index, which uses routine lab values and age to estimate the risk of fibrosis. The goal is to identify who is low risk, who needs closer monitoring, and who may need more advanced testing. I also cover treatment options. The most important treatment is improving metabolic health, especially weight loss and better control of diabetes. For some patients, there are medication options that may help when the disease has progressed to higher risk fibrosis categories, including resmetirom and semaglutide, alongside lifestyle changes. My message at the end is straightforward. Fatty liver disease is common, it can become serious, and we can do something about it when we catch it early. I want patients to feel empowered to ask about their risk and I want clinicians to make this a routine part of proactive care, because better conversations and earlier screening lead to better outcomes.
💡 Start your journey today with Maryland Primary Care & Wellness
Book your consultation: https://www.maryland-primarycare.com/
0 23 hours ago
0 1 week ago
We tackle the health topics no one else wants to touch
—From obesity and high blood pressure
—To emotional eating and medication resistance
—To cultural myths that keep people sick
My mission is to deliver evidence-based truth—no sugarcoating, culture-aware, and guided by medicine.
© Dr Albert Takem
Are you sure you want to cancel your subscription? You will lose your Premium access and stored playlists.
✖
Be the first to leave a comment